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Type 2 diabetes mellitus is a metabolic disorder
characterized by hyperglycemia, insulin resis-
tance in peripheral tissues, and altered insulin
secretory capacity of pancreatic β-cells. Type 2
diabetes accounts for 90–95% of all cases of
diabetes and is a major public health problem
worldwide (Wild et al. 2004). Established risks
factors of type 2 diabetes include older age,
obesity, physical inactivity, family history, and
genetic polymorphisms. In addition, environ-
mental toxicants, including arsenic, have been
suggested to play an etiologic role in diabetes
development (Longnecker and Daniels 2001).
Arsenic is a recognized toxicant and car-
cinogen. Nonoccupational exposure occurs
mainly through drinking water, affecting mil-
lions of people worldwide. Exposure to levels
of arsenic in drinking water well above
100 ppb has been associated with an increased
risk of type 2 diabetes in the high-arsenic areas
of Taiwan and Bangladesh(Lai et al. 1994;
Rahman et al. 1998). The biological mecha-
nisms for an association between chronic
arsenic exposure and increased diabetes risk are
not known [National Research Council
(NRC) 1999, 2001; Tseng 2004].
Previous reviews of the role of arsenic in
diabetes have questioned the quality of the
evidence but were supportive of the possibility
of an association [NRC 1999, 2001; Ng
2001; Tseng 2004; Tseng et al. 2000, 2002;
World Health Organization (WHO) 2001].
These reviews, however, did not use system-
atic review criteria and may be subject to
biased selection of the evidence. Our objective
was to perform a systematic review of the
experimental and epidemiologic evidence on
arsenic and type 2 diabetes. We examined
experimental studies (in vitro or in vivo) to
synthesize available information on plausible
mechanisms for the effect of arsenic on glu-
cose metabolism, as well as epidemiologic
studies to synthesize the association of arsenic
exposure with diabetes risk in humans.
Materials and Methods
Search strategy and study selection. We
searched the Medline database (http://
www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=PubMed) and the TOXNET data-
base [consisting of TOXLINE, GENETOX,
and DART/ETIC (Developmental and
Reproductive Toxicology/ Environmental
Teratogen Information Center); http://
toxnet.nlm.nih.gov/] from 1966 through July
2005 using free text and the medical subject
headings (MeSH) arsenic, arsenite, arsenate,
arsenicals, diabetes, glucose, glycosylated hemo-
globin, insulin, and mortality. In addition, we
manually reviewed the reference lists from rele-
vant original research and review articles.
For experimental studies, we identified
in vitro or in vivo studies of the administration
of arsenic or arsenic compounds, including
inorganic arsenite (trivalent arsenic), inorganic
arsenate (pentavalent arsenic), and others, and
outcomes related to diabetes status or glucose
and insulin metabolism. For epidemiologic
studies, we identiﬁed studies assessing arsenic
exposure through measures of environmental
samples, biomarkers, or indirect measures
(e.g., job titles reflecting occupational expo-
sure or living in areas with known exposure
via drinking water) and diabetes status or
markers of glucose metabolism.
The exclusion criteria for experimental
and epidemiologic studies were a) no original
research (reviews, editorials, nonresearch let-
ters); b) studies performed only on people
with diabetes, including case reports; c) lack
of outcomes related to diabetes or glucose
metabolism; d) no data on arsenic exposure;
e) experiments in nonmammalian cells, or
noncellular experiments; f) animal studies
administering a single dose of arsenic; and
g) culture cell experiments using lewisite or
oxophenylarsine. Figure 1 summarizes the
study selection process.
Two investigators (A.N.-A., R.A.S.) inde-
pendently abstracted the articles that met the
selection criteria. Discrepancies were resolved
by consensus. We converted all arsenic
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Chronic arsenic exposure has been suggested to contribute to diabetes development. We performed
a systematic review of the experimental and epidemiologic evidence on the association of arsenic
and type 2 diabetes. We identiﬁed 19 in vitro studies of arsenic and glucose metabolism. Five stud-
ies reported that arsenic interfered with transcription factors involved in insulin-related gene
expression: upstream factor 1 in pancreatic β-cells and peroxisome proliferative-activated receptor γ
in preadipocytes. Other in vitro studies assessed the effect of arsenic on glucose uptake, typically
using very high concentrations of arsenite or arsenate. These studies provide limited insight on
potential mechanisms. We identiﬁed 10 in vivo studies in animals. These studies showed inconsis-
tent effects of arsenic on glucose metabolism. Finally, we identiﬁed 19 epidemiologic studies (6 in
high-arsenic areas in Taiwan and Bangladesh, 9 in occupational populations, and 4 in other popu-
lations). In studies from Taiwan and Bangladesh, the pooled relative risk estimate for diabetes com-
paring extreme arsenic exposure categories was 2.52 (95% confidence interval, 1.69–3.75),
although methodologic problems limit the interpretation of the association. The evidence from
occupational studies and from general populations other than Taiwan or Bangladesh was inconsis-
tent. In summary, the current available evidence is inadequate to establish a causal role of arsenic in
diabetes. Because arsenic exposure is widespread and diabetes prevalence is reaching epidemic pro-
portions, experimental studies using arsenic concentrations relevant to human exposure and
prospective epidemiologic studies measuring arsenic biomarkers and appropriately assessing dia-
betes should be a research priority. Key words: arsenic, diabetes, glucose metabolism, meta-analysis,
systematic review. Environ Health Perspect 114:641–648 (2006). doi:10.1289/ehp.8551 available
via http://dx.doi.org/ [Online 15 December 2005]concentrations to parts per million (ppm) or
parts per billion (ppb), including concentra-
tions from in vitro studies, which were usually
reported in molar units of arsenic (1 µM of
arsenic = 74.9 µg/L = 74.9 ppb).
Statistical methods. Measures of association
in epidemiologic studies (odds ratios, preva-
lence ratios, standardized mortality ratios, rela-
tive risks, relative hazards, comparisons of
means) and their SE values were abstracted or
derived using data reported in the articles
(Greenland 1987). Within each study, we used
the model adjusted for the most covariates.
Adjustment did not substantially modify the
conclusions of any individual study. For ﬁve
studies, we used data available in the original
articles to derive relative risk estimates. For one
study (Lagerkvist and Zetterlund 1994),
because there were no cases among the unex-
posed, we added 0.5 to each cell to estimate
the relative risk and the 95% conﬁdence inter-
val (CI). For Jensen and Hansen (1998), we
compared the proportion of subjects with gly-
cosylated hemoglobin above 7% across occupa-
tional exposure categories. For Ward and Pim
(1984) and Ruiz-Navarro et al. (1998), we
used the linear discriminant function method
to estimate relative risks from comparisons of
means (Greenland 1987). Finally, for Lewis
et al. (1999), we estimated the relative risk of
diabetes mortality comparing the highest with
the lowest category of exposure within the
cohort from the published standardized
mortality ratios.
We grouped the studies in three cate-
gories: studies in general populations exposed
to high arsenic levels, corresponding to studies
in Taiwan and Bangladesh with average levels
in drinking water well above 100 ppb; studies
in occupational populations exposed to high
arsenic levels most commonly in ambient air;
and studies in general populations exposed to
low or moderate levels of arsenic in drinking
water (< 100 ppb), food, or ambient air.
Because of substantial heterogeneity and
methodologic limitations, we present a quali-
tative systematic review, and we used only
meta-analysis techniques for studies from
Taiwan and Bangladesh. For descriptive pur-
poses, we report the range and the unweighted
medians of the relative risk of diabetes com-
paring extreme categories of arsenic exposure
in each study.
Results
In Vitro Experimental Studies
Nineteen in vitro studies published between
1965 and 2004 met our inclusion criteria
(Figure 1, Table 1). None of the experimental
studies were conducted in human cell lines.
Five experiments investigated the effect of
arsenic on insulin signal transduction and
gene expression. Three studies were performed
in transfected mouse pancreatic β-cells, where
exposure to high arsenite concentrations was
similar to high glucose in stimulating insulin
upstream factor 1 (IUF-1) (Macfarlane et al.
1997) and in stimulating the translocation of
IUF-1 from the cytoplasm to the nucleus
(Elrick and Docherty 2001; Macfarlane et al.
1999). IUF-1, also called homeodomain tran-
scription factor PDX1, is a transcription factor
that binds to the human insulin gene pro-
moter and increases insulin messenger RNA
levels in response to glucose. The effect of
high glucose or arsenite was prevented by
SB 203580, a specific inhibitor of stress-
activated protein kinase-2 (SAPK2)/p38,
whereas the effect of high glucose but not of
arsenite was prevented by substances that
specifically inactivate phosphatidylinositol-3
kinase (wortmannin and LY294002). Two
other studies (Salazard et al. 2004; Wauson
et al. 2002) investigated the role of arsenite in
adipocyte differentiation and peroxisome pro-
liferative-activated receptor γ (PPARγ) expres-
sion. PPARγ is a transcription factor that
regulates key gene expression for insulin sensi-
tivity. These two experiments used different
concentrations and lengths of exposure and
produced opposite results. In the study by
Salazard et al. (2004), the incubation of
3T3-F442A preadipocytes with 1.7 and 3 ppb
(0.25 and 0.5 µM) arsenite for 3 days induced
the expression of PPARγ and CCAAT/
enhancer binding protein. In study by
Wauson et al. (2002), the incubation of C3H
101T1/2 cells with 450 ppb (6 µM) arsenite
for 2 months prevented adipocyte differentia-
tion through the inhibition of the PPARγ.
Arsenite also inhibited the differentiating
effect induced by pioglitazone, a PPARγ agonist
used to reduce insulin resistance.
The rest of the in vitro studies assessed the
effect of arsenic on glucose uptake, typically
using very high concentrations of arsenite as
general inducers of cellular stress. Ten studies
measured basal glucose uptake (in the absence
of insulin) in cell lines exposed to arsenite or
other compounds (Table 1, Figure 2). Four of
the studies also exposed the cells simultane-
ously to insulin and arsenite (Table 2).
Compared with insulin alone, simultaneous
exposure to insulin and arsenite decreased
glucose uptake in insulin-sensitive cells
(Bazuine et al. 2003; Walton et al. 2004).
One of the studies (Walton et al. 2004) meas-
ured basal and insulin-stimulated glucose
uptake in cells exposed to arsenate and to
methylated arsenic compounds.  Methylarsine
oxide (MAsIIIO) inhibited insulin-stimulated
glucose uptake at the concentration of 75 ppb
after 4- or 24-hr exposure (Walton et al.
2004). For arsenite, because the concentra-
tions used in glucose uptake studies were
extremely high, their relevance to diabetes
development in humans is questionable.
Overall, in vitro studies provided limited
insight into potential mechanisms that may
explain an etiologic role of arsenic on diabetes.
In Vivo Experimental Studies
Ten experimental studies in mice, rats, goats,
and guinea pigs published between 1979 and
2004 met our inclusion criteria (Figure 1,
Table 3). Arsenite was evaluated in 6 studies
(Biswas et al. 2000; Cobo and Castineira 1997;
Ghafghazi et al. 1980; Pal and Chatterjee
2004a, 2004b, 2005), and arsenate in 2 studies
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Distinct references identified (n = 1,042)
Medline search: 964
Toxnet (not in Medline): 61
Hand search: 17
References excluded (n = 994)
No original data
Case report/case series
No diabetes/glucose-related outcome
Nonmammalian cells
Noncellular systems
Animal studies with a single dose
Lewisite and oxophenylarsine experiments
Experimental studies (n = 29)
–In vitro: 19
–Signal transduction and gene expression: 5
–Glucose uptake: 10
–Miscellaneous: 4
–In vivo: 10
Epidemiologic studies (n = 19)
–High exposure, general populations: 6
–High exposure, occupational populations: 9
–Low/moderate exposure, general populations: 4
Figure 1. Flow diagram of the experimental and epidemiologic study selection process.(Aguilar et al. 1997; Hughes and Thompson
1996). Other compounds were methanear-
sonate (Judd 1979) and monomethylarsenic
(Arnold et al. 2003). Six studies administered
arsenic in water or food for lengths of time
ranging from 4 weeks to 2 years, and 5 studies
involved intraperitoneal exposure to arsenic for
5–30 days. The doses of arsenic were high or
very high in most studies, with a lowest dose of
5.55 ppm arsenite (Pal and Chatterjee 2004a)
and 0.025 ppm arsenate (Hughes and
Thompson 1996).
Although all studies measured glucose lev-
els in blood, plasma, or serum, only one study
provided information on potential mecha-
nisms (Cobo and Castineira 1997). In this
study, the oral administration of arsenite did
not affect insulin levels in vivo. However, a
glucose stimulus applied ex vivo produced
greater insulin release from the isolated pan-
creas cells of rats treated with arsenite in vivo
compared with the insulin release from
isolated pancreas cells of control rats.
Epidemiologic Studies
Study characteristics. Nineteen epidemiologic
studies met our inclusion criteria (Figure 1,
Systematic review of arsenic and diabetes
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Table 1. In vitro studies of arsenic exposure and glucose metabolism outcomes. 
Source Type of cell/tissue Compound Dose (ppm) Incubation Outcomes and results (compared with controls)
Signal transduction and gene expression
Macfarlane et al. 1997 Pancreatic β-cells Arsenite 37.5 0.33 hr ↑ IUF-1 dependent gene expression
PI-3 kinase independent; SAPK2/p38 involved
Macfarlane et al. 1999 Pancreatic β-cells Arsenite 75 0.5 hr ↑ IUF-1 translocation from cytoplasm to nucleus
PI-3 kinase independent; SAPK2/p38 involved
Elrick and Docherty 2001 Pancreatic β-cells Arsenite 75 0.5 hr ↑ IUF-1 translocation from cytoplasm to nucleus
PI-3 kinase independent; SAPK2/p38 involved
Wauson et al. 2002 C3H 10T1/2 Arsenite 0.45 2 months ↓ PPARγ mRNA
preadipocytes ↓ Pioglitazone-stimulated adipocyte differentiation
Salazard et al. 2004 3T3-F442A Arsenite 0.0017, 3 days ↑ Expression of PPARγ and C/EBPα (genes with important roles in adipose
preadipocytes 0.003 determination)
Glucose uptake in cultured cells
Warren et al. 1986 BHK-21 cells Arsenite 3.75 2 hr ↑ Basal glucose uptake; = insulin-stimulated glucose uptake
= amino acid uptake
Widnell et al. 1990 BHK-21 cells Arsenite 15 2 hr ↑ Basal glucose uptake; ↑ glucose transporter translocation (reversible)
Pasternak et al. 1991 BHK-21 cells Arsenite 4.5–7.5 2 hr ↑ Basal glucose uptake (reversible when arsenite removed)
Fast and reversible translocation of glucose receptor
Liebl et al. 1992 MDCK dog cells Arsenite 37.5–75  1 hr ↓ Basal glucose uptake, dose dependent
Sviderskaya et al. 1996 BHK cells Arsenite 7.5–22.5 2 hr ↑ Basal glucose uptake, dose dependent 
3T3-L1 adipocytes ↑ Glucose transporter translocation in both types of cells
McDowell et al. 1997 L6 rat muscle cells Arsenite 7.5–112.5 0.5 hr ↑ Basal glucose uptake, dose dependent but maximal with 37.5 ppm
↑ GLUT1 and GLUT4 in cell membrane, PI-3 kinase independent
↑ Insulin-stimulated glucose uptake
Fladeby and Serck- Bovine adrenal cells Arsenite 1.88–18.8  1 hr ↑ Basal glucose uptake up to 7.5 ppm, then plateau
Hanssen 1999 PI-3 kinase independent, SAPK2/p38 partly involved
Bazuine et al. 2003 3T3-L1 adipocytes Arsenite 0.75–75  0.5 hr ↑ Basal glucose uptake up to 37.5 ppm, then ↓
↓ Insulin-stimulated glucose uptake
↑ GLUT4 and GLUT1 translocation (but less than insulin)
PI-3 kinase independent; no changes in IRβ, IRS-1, IRS-2
No phosphorylation of PKB; PKC-λ/ζ and SAPK2/p38 involved
Bazuine et al. 2004 3T3-L1 adipocytes Arsenite 3.75–750  0.5 hr ↑ Basal glucose uptake up to 37.5 ppm
Dexamethasone ↓ arsenite glucose uptake
SAPK2/p38 involved
Walton et al. 2004 3T3-L1 adipocytes Arsenite 1.5, 7.5 4 hr = basal glucose uptake at 1.50 ppm, ↓ at 7.5 ppm, ↓ insulin-stimulated
MAsIIIO 0.08, 0.4 = basal glucose uptake at 0.08 ppm, ↓ at 0.4 ppm, ↓ insulin-stimulated
DMAsIIII 0.15, 0.75 = basal glucose uptake all doses, ↓ insulin-stimulated
Arsenate 7.5, 75 ↑ basal glucose uptake at 7.5 ppm, ↓ at 75 ppm, = insulin-stimulated
MAsV 7.5, 75 = basal glucose uptake all doses, ↓ insulin-stimulated
DMAsV 7.5, 75 = basal and insulin-stimulated glucose uptake all doses,
PI-3 kinase independent. No changes in IRβ and IRS-2
MAsIIIO and DAsIIII, but not arsenite IRS-1, ↑ phosphorylation of IRS-1
Arsenite, MAsIIIO and DAsIIII ↓ phosphorylation of PKB/Akt
Arsenite, MAsIIIO and DAsIIII ↓ GLUT4 translocation in insulin-treated cells
Arsenite 0.4, 0.8, 1.5 24 hr Dose-dependent ↓ insulin-stimulated glucose uptake
MAsIIIO 0.02, 0.04, 0.08 = insulin-stimulated glucose uptake at 0.02 ppm, ↓ at 0.04 and 0.08
DMAsIIII 0.04, 0.08, 0.15 = insulin-stimulated glucose uptake all doses
Miscellaneous experiments
Short et al. 1965 Rat hemidiaphragms Arsenite 75 1–3 hr ↑ Basal glucose uptake in hemidiaphragms; ↑ uptake with arsenate in
Epidydimal fat pads Arsenate 75 fat pads = insulin stimulated glucose uptake in hemidiaphragm; ↓uptake with
arsenite in fat pad
Dixit and Lazarow 1967 Epidydimal fat pads Arsenite 0.75–7,500  3 hr ↑ Basal glucose oxidation up to 7.5 ppm
Brazy et al. 1980 Rabbit kidney tubules Arsenate 0.75–375 0.5 hr ↓ Fluid, phosphate, and glucose absorption (lumen to bath)
Hunder et al. 1993 Rat jejunal segments Arsenite 0.19–18.9 2 hr ↓ Intestinal glucose transfer dose dependent (= arsenate < 7.5 ppm)
Arsenate 0.19–187.5
1 ppm = 13.35 µM. Basal glucose uptake, glucose uptake in the absence of insulin. ↑, increase; ↓, decrease; = similar levels; BHK-21 cells, baby hamster kidney cells (contain predomi-
nantly GLUT1); C/EBPα, CCAAT/enhancer binding protein; DAsIIII, iododimethylarsine; DMAsV, dimethylarsinic acid; GLUT, glucose transporter; IRβ: insulin receptor β; IRS, insulin receptor
substrate; IUF-1, insulin upstream factor-1 (also called homeodomain transcription factor PDX1); MAsIIIO, methylarsine oxide; MAsV, monosodium methyl arsenate; MDCK dog cells,
Madin-Darby canine kidney cells; ppm, part per million; PI-3 kinase, phosphatydilinositol-3 kinase; PKB, protein kinase B; PKC, protein kinase C; PPARγ, peroxisome proliferative-activated
receptor γ; SAPK2, stress activator protein kinase 2 (also called p38 mitogen-activated protein kinase).Table 4). Three studies were published
between 1980 and 1984 (Enterline and Marsh
1982; Mabuchi et al. 1980; Ward and Pim
1984), and the other 15 were reported between
1994 and 2004. Only 2 studies used a prospec-
tive cohort design (Lewis et al. 1999; Wang
et al. 2003). The rest used cross-sectional,
case–control, or retrospective cohort designs.
Two studies used the WHO diabetes defini-
tion based on oral glucose tolerance tests
and/or self-reported medication to deﬁne dia-
betes, whereas the other studies used death cer-
tificates, medical or insurance records, urine
tests for glucosuria, self-reported diabetes
symptoms such as polyuria conﬁrmed by two
positive urine tests and a positive oral glucose
tolerance test, glycosylated hemoglobin, or
self-reported diagnosis. Two studies did not
specify the diagnostic criteria. The number of
diabetes cases ranged from 2 (Mabuchi et al.
1980) to 27,543 (Wang et al. 2003), but most
studies had fewer than 100 cases. Studies in
general populations included adult men and
women, whereas occupational studies included
mostly men.
There were substantial differences in
arsenic exposure ascertainment. Most studies
in general populations assessed exposure indi-
rectly, using measurements of total arsenic lev-
els in community drinking water sources. Two
studies from Taiwan (Lai et al. 1994; Tseng
et al. 2000), one from Bangladesh (Rahman
et al. 1999), and one from the United States
(Lewis et al. 1999) estimated a cumulative
arsenic exposure index (ppm-year) by multiply-
ing the number of years that individuals lived
in a speciﬁc village/area by the average arsenic
level in drinking water in that village/area (usu-
ally, in each area, several measurements were
performed once in time). Other studies in
Taiwan and Bangladesh assigned exposure on
the basis of residence in an area determined to
be endemic for arseniasis (Rahman et al. 1998;
Tsai et al. 1999; Wang et al. 2003). None of
the studies from Taiwan or Bangladesh
obtained individual measures of arsenic expo-
sure either from household tap water measures
or more directly by using biomarkers of expo-
sure. None of these studies assessed potential
sources of exposure other than drinking water.
In occupational studies, exposure was based on
job title or on estimated arsenic levels in air for
different job categories as assessed by a safety
engineer (Rahman and Axelson 1995). One
study in an occupationally exposed area
assessed arsenic exposure based on years of
residence within 4 km of a copper smelter dur-
ing childhood (Tollestrup et al. 2003). Some
occupational studies (Enterline and Marsh
1982; Jensen and Hansen 1998; Lagerkvist
and Zetterlund 1994; Lubin et al. 2000) also
measured arsenic in urine or air to confirm
exposure, but this information was not linked
to diabetes in the analyses. Only two studies
used biomarkers of exposure: Ward and Pim
(1984) measured total arsenic in plasma, and
Ruiz-Navarro et al. (1998) measured total
arsenic in urine, without speciation of
inorganic and methylated compounds.
Quality assessment. In the epidemiologic
studies we abstracted information to evaluate
study quality, adapting the criteria proposed
for observational studies by Longnecker et al.
(1988). As shown in Table 5, most studies
failed to fulﬁll important quality criteria such
as individual measures of arsenic exposure
using biomarkers, standard criteria to diag-
nose diabetes, or information on established
risk factors for diabetes.
Relative risk estimates. The relative risk
estimates comparing the highest with the low-
est arsenic exposure categories are shown in
Table 4. Studies in Taiwan and Bangladesh
consistently identiﬁed an increased risk of dia-
betes with increased arsenic exposure, with rel-
ative risks ranging from 1.46 to 10.1 (median,
2.40) and with a pooled relative risk estimate
using and inverse variance weighted random-
effects model of 2.52 (95% CI, 1.69–3.75;
p heterogeneity < 0.001). Occupational studies
were small and showed no consistent pattern,
with relative risks ranging from 0.34 to 9.61
(median, 1.40). We identiﬁed only 4 studies in
general populations from countries with low or
moderate arsenic exposure. These studies were
small and did not show an increased risk of
diabetes with increasing arsenic levels (relative
risks ranged from 0.65 to 1.09; median, 0.95).
Navas-Acien et al.
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Figure 2. Ratio of basal glucose uptake in periph-
eral cell lines comparing arsenite versus control.
Lines represent the dose response for each inde-
pendent study. Single points represent the effect
for studies using a single dose (1 ppm = 13.35 µM;
0.75 ppm = 10 µM).
Table 2. Experimental characteristics and ratio of glucose uptake in peripheral cell lines exposed to arsenite
and insulin compared with insulin and arsenite alone.
Experiment characteristics Ratio of glucose
Incubation Arsenite uptake vs.
Source Type of cell (hr) (ppm) Insulin (nM) Insulin Arsenite
Warren et al. 1986 BHK-21 cells 2 3.75 100 0.94 0.91
McDowell et al. 1997 L6 rat muscle cells 0.5 37.5 100 1.42 1.21
Bazuine et al. 2003 3T3-L1 adipocytes 0.5 37.5 100 0.57 1.33
Walton et al. 2004 3T3-L1 adipocytes 4 1.50 1,000 0.60 0.55
Walton et al. 2004 3T3-L1 adipocytes 4 7.49 1,000 0.20 0.33
BHK-21 cells, baby hamster kidney cells. For arsenite, 1 ppm = 13.35 µM.
Table 3. In vivo studies of arsenic exposure and glucose metabolism.
Experimental Daily dose
Source animal n Compound (route) (ppm) Duration Outcomes and results (compared with controls)
Judd 1979 Field mice 19 Methanearsonate (po inwater) 1,000 30 days ↓ Blood glucose, = ﬂuid and food consumption
Ghafghazi et al. 1980 Rats 12 Arsenite (ip) 5–10 7 days ↑Glucose levels after glucose tolerance test, dose dependent
Hughes and Thompson 1996 B6C3F1 mice 72 Arsenate (po in water) 0.025–2.5 28 days ↓ Plasma glucose, = ﬂuid and food consumption
Aguilar et al. 1997 Wistar rats 20 Arsenate (po in food) 5 10 weeks = Plasma glucose levels
Cobo and Castineira 1997 Wistar rats 21 Arsenite (po in water) 17.75 1st week Delayed glucose clearance after glucose tolerance test
up to 100 8th week = Basal insulin levels in vivo
Biswas et al. 2000 Bengal goats 12 Arsenite (po in capsule) 25 12 weeks ↑ Blood glucose at week 6 and ↑↑ at week 12
Arnold et al. 2003 Fischer rats 480 Monomethylarsenic (po in food) 50–1,300 2 years = Blood glucose levels up to 400 ppm, ↓ with 1,300 ppm
Pal and Chatterjee 2004a Wistar rats 18 Arsenite (ip) 5.55 21 days ↓ Blood glucose (reversed with methionine)
= Body, liver, kidney weight
Pal and Chatterjee 2004b Wistar rats 18 Arsenite (ip) 5.55 30 days ↓ Blood glucose (reversed with N-acetylcysteine)
Pal and Chatterjee 2005 Wistar rats 18 Arsenite (ip) 5.55 30 days ↓ Blood glucose (reversed with methionine)
Abbreviations: ip, intraperitoneal; po, per oral; ↑, increase; ↓, decrease.Five studies provided information on the
dose response in diabetes risk by cumulative
arsenic exposure in drinking water (Figure 3).
Diabetes risk tended to increase with increas-
ing cumulative exposure in studies from
Taiwan (Lai et al. 1994; Tseng et al. 2000)
and Bangladesh (Rahman et al. 1999). No
trend was observed in the U.S. studies (Lewis
et al. 1999; Zierold et al. 2004).
Discussion
Summary of findings. The evidence on the
association of arsenic exposure with diabetes
risk summarized in this systematic review is
inconclusive. Evidence from in vitro studies
suggests that arsenic interferes with signal
transduction and transcription factors that are
related to insulin pathways such as IUF-1 in
pancreatic cells or PPARγ in preadipocytes.
In vitro glucose uptake experiments and
in vivo studies did not provide evidence on
potential mechanisms that may explain a
diabetogenic effect of arsenic. In general,
experimental studies were limited by the use of
arsenic concentrations that were much higher
than those relevant to human exposure. For
example, the current U.S. Environmental
Protection Agency recommended standard for
arsenic in drinking water is 10 ppb. The low-
est concentration of arsenite used in studies of
cultured cells investigating glucose uptake was
750 ppb (Bazuine et al. 2003), and the lowest
concentration of arsenite in animal studies was
5,550 ppb (Pal and Chatterjee 2004a, 2004b).
In epidemiologic studies, the association
between arsenic exposure and diabetes across
different populations and different sources of
exposure was inconsistent. In populations
exposed to high arsenic levels via drinking
water in Taiwan and Bangladesh, diabetes risk
was consistently increased. In occupational
settings, diabetes mortality was increased in
some studies and decreased in others. Finally,
no association with diabetes was observed in
four studies of general populations outside of
Taiwan or Bangladesh. Overall, the quality of
the epidemiologic evidence was limited by
methodologic problems, particularly in assess-
ing arsenic exposure and diabetes outcomes.
Mechanisms for arsenic-related diabetes.
Acute arsenite toxicity, including its effects on
glucose metabolism, is generally attributed to
its reactivity toward thiol (SH) groups
(Aposhian 1989; NRC 1999). During acute
Systematic review of arsenic and diabetes
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Table 4. Epidemiologic studies of arsenic exposure and diabetes.
Diabetes Cases/ Men Age range Arsenic Levels, exposed RR of diabetes
Source Design Country Population diagnosis noncases (%) (year) assessment vs. reference (95% CI) Adjusted for
General populations, high arsenic exposure
Lai et al. 1994 CS Taiwan Survey of participants OGTT or 86/805 43 30–69 CEI village > 15 vs. 0 ppm-year 10.1 (1.30–77.9) Age, sex, BMI,
in high-arsenic area self-reported drinking water physical
activity
Tsai et al. 1999 RCO Taiwan Deaths in 1971–1994 Death certiﬁcate 531 deaths 35 All ages Living in HAA HAA vs. no HAA 1.46 (1.28–1.67) Age, sex
Tseng et al. CO Taiwan Survey of participants OGTT 41/405 50 Mean 47 CEI village > 17 vs.  < 17 2.10 (1.10–4.20) Age, sex, BMI
2000 in high-arsenic area drinking water ppm-year
Wang et al. CS Taiwan  National Health ICD-9 250 27,543/ 43 25–65+ Living in HAA  HAA vs. no HAA 2.69 (2.65–2.73) Age, sex
2003 Insurance Database ICD-9 A181 678,791
Rahman et al. CS Bangla- Survey participants Self-reported 46/971 59 30–60+ Living in HAA Keratosis vs. 5.90 (2.90–11.6) Age, sex, BMI
1998 desh in high- and symptoms +  and keratosis no keratosis
low-arsenic areas glucosuria +
OGTT
Rahman et al. CS Bangla- Survey participants Glucosuria 263/1,332 61 30–60+ CEI village > 10 vs. 0 ppm-year 2.10 (1.10–4.20) Age, sex
1999 desh in high-arsenic area drinking water
Occupational populations, high arsenic exposure
Mabuchi et al. RCO U.S. Pesticide workers, Death certiﬁcate 2 deaths 75 < 20–40+ Job title Workers vs. general 0.47 (0.12–1.88) Age, sex,
1980 Baltimore, MD at hire population period
Enterline and RCO U.S. Copper smelter Death certiﬁcate 12 deaths 100 < 20–69 Job title Workers vs. general 0.85 (0.48–1.49) Age
Marsh 1982 workers, Washington  at hire population
State
Lagerkvist and CS Sweden Copper smelter Self-reported 4/85 100 Mean 57 Job title Workers vs. other 9.61 (0.53–173) Crude
Zetterlund 1994 workers, other jobs type 2 diabetes workers
Rahman and CC Sweden Copper smelter Death certiﬁcate, 12/31 100 30–74 at Air levels ~ 5 vs. 0 mg/m3 3.30 (0.50–30.0) Age
Axelson 1995 workers medical record death
Rahman et al. CC Sweden Deaths in glass Death certiﬁcate 240/2,216 100 45–75+ Job title Workers vs. other 1.40 (0.90–2.10) Age
1996 industry area workers
Jensen and  CS Denmark Taxidermists, wood HbA1c 5/59 87 Mean 37 Job title Workers vs. general 4.43 (0.47–42.0) Age
Hansen 1998 workers, other jobs population
Bartoli et al. RCO Italy Glass industry Death certiﬁcate 3 deaths 100 < 40–65+ Job title Workers vs. general 0.34 (0.09–0.88) Age
1998 workers population
Lubin et al. 2000 RCO U.S. Copper smelter Death certiﬁcate 54 deaths 100 < 20–30+ Job title Workers vs. general 0.83 (0.63–1.08) Age
workers, Montana at hire population
Tollestrup et al. RCO U.S. Children < 4 km of Death certiﬁcate 16/3,116 58 < 14 Years of ≥ 10 vs. < 1 year 1.60 (0.36–1.16) Crude
2003 Copper smelter residency
General populations, low to moderate arsenic exposure
Ward and Pim CC UK Hospital based NR 87/30 65 18–78 Plasma levels 75th vs. 25th  1.09 (0.79–1.49) Crude
1984 (NAA) percentile
Ruiz-Navarro CC Spain Hospital based NR 38/49 39 NR Urinary levels 75th vs. 25th   0.87 (0.50–1.53) Crude
et al. 1998 (AAS) percentile
Lewis et al. CO U.S. Mormons Death certiﬁcate 55/4,003 52 < 50–80+  CEI community > 4 vs. < 1  0.65 (0.34–1.24) Age, sex
1999 drinking water ppm-year
Zierold et al. CC U.S. Survey participants Self-reported 67/1118 NR Mean 62 Subject >  10  vs. < 2 ppb 1.02 (0.49–2.15) Age, sex, BMI,
2004 with private wells drinkingwater smoking
Abbreviations: AAS, atomic absorption spectrometry; BMI, body mass index; CC, case–control; CEI, cumulative exposure index: Σ arsenic levels in drinking wateri × time of exposurei
(i indicates speciﬁc village); CO, cohort; CS, cross-sectional; HAA, high-arsenic area; HbA1c, hemoglobin A1c; ICD-9, International Classiﬁcation of Diseases, Ninth revision; NAA, neu-
tron activation analysis; NR, not reported; OGTT, oral glucose tolerance test, criteria for a positive test based on the WHO criteria; RCO, retrospective cohort; RR, relative risk. Navas-Acien et al.
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poisoning, arsenite inhibits pyruvate and
α-ketoglutarate dehydrogenases (Aposhian
1989), essential enzymes for gluconeogenesis
and glucolysis. The interference of arsenic
with pyruvic acid metabolism was described
by Krebs in the early 1930s (Krebs 1933).
Arsenate, on the other hand, can replace phos-
phate in energy transfer pathways of phospho-
rylation and also uncouples oxidative
phosphorylation (Kennedy and Lehninger
1949). However, these toxic effects of acute
arsenic exposure are unlikely to occur as a
result of chronic exposure to environmentally
relevant doses (Tseng 2004).
The inﬂuence of arsenic on the expression
of gene transcription factors may be related to
diabetes risk. However, the effects of arsenite on
IUF-1 and PPARγ were contradictory in terms
of diabetes development. The differential effects
may reﬂect a complex dose–response pattern
for arsenic or differences in length of exposure
to arsenic across studies. Further studies with
wide ranges and durations of arsenic exposure
are needed to investigate the effect of arsenic on
these and other insulin-related events at the cel-
lular and molecular levels. For instance, inter-
ference with the glucocorticoid receptor is
another potential mechanism for arsenic-related
diabetes that deserves further investigation.
Arsenic shows a complex dose–response effect
on glucocorticoid receptor mediated transcrip-
tion (Bodwell et al. 2004), with a stimulatory
effect at very low concentrations (6–120 ppb)
and an inhibitory effect at doses greater than
120 ppb. The glucocorticoid receptor is a
member of the steroid receptor superfamily that
among other metabolic processes regulates
gluconeogenesis. Reduction of glucocorticoid
receptor expression in hepatic and adipose tis-
sue has been shown to improve hyperglycemia
in diabetic rodents (Watts et al. 2005).
Experimental studies on glucose uptake
showed that arsenite increases uptake inde-
pendently of the earlier steps of the insulin
transduction pathway, although when co-
administered with insulin, arsenite inhibited
insulin-stimulated glucose uptake in 3T3-L1
adipocytes. The purpose of most of these stud-
ies was to investigate the role of stress in glu-
cose uptake, which is unrelated to the
possibility that arsenic could affect diabetes
risk. Under these designs, cultured cells were
exposed to high arsenic levels for a few hours,
whereas humans are chronically exposed to
lower concentrations. Only one study investi-
gated methylated arsenical compounds and
their interference in insulin signaling in
adipocytes (Walton et al. 2004). For these rea-
sons, the relevance of in vitro glucose uptake
ﬁndings to diabetes etiology is uncertain.
Arsenic could inﬂuence diabetes develop-
ment by other mechanisms, including oxida-
tive stress, inflammation, or apoptosis,
nonspeciﬁc mechanisms that have been impli-
cated in the pathogenesis of type 2 diabetes.
Arsenic exposure can enhance the production
of reactive oxygen species (Barchowsky et al.
1999; Chen et al. 1998; Tseng 2004; Wang
et al. 1996), interfere with the activity of key
antioxidant enzymes such as glutathione
reductase, glutathione S-transferase, glu-
tathione peroxidase, and glucose 6-phosphate
dehydrogenase (Maiti and Chatterjee 2000;
Santra et al. 2000), and induce lipid peroxida-
tion (Santra et al. 2000). In individuals from
Taiwan, increasing blood levels of arsenic cor-
related with increasing levels of reactive oxygen
species and with decreasing levels of antioxi-
dant capacity in plasma (Wu et al. 2001).
Arsenic may also up-regulate interleukin-6 and
other inflammatory cytokines (Wu et al.
2003), and it may induce the release of tumor
necrosis factor-α from mononuclear cells (Yu
et al. 2002). Finally, arsenic is well known for
inducing apoptosis in multiple cell lines
(Waalkes et al. 2000). Future research should
evaluate whether these mechanisms mediate
the role of arsenic in diabetes development.
The in vivo experimental studies were
mostly uninformative. The diversity of species
studied probably reflects that there are no
good animal models to study the effects of
arsenic on diabetes development. Indeed, the
classiﬁcation of arsenic as a human carcinogen,
although recently supported by animal models
(Waalkes et al. 2004), was for a long time
based on human data. Progress in the study of
the role of arsenic in diabetes requires the
identiﬁcation of appropriate animal models.
Arsenic and diabetes in human studies.
Suggestive evidence links chronic exposure to
high arsenic levels in drinking water with
increased diabetes risk in Taiwan and
Bangladesh. Methodologic problems, how-
ever, limit the causal interpretation of this
association. The use of average drinking water
and the lack of individual measures of arsenic
make it possible to underestimate exposure
All studies (n = 19)
Diabetes diagnosis based on fasting glucose levels or oral glucose tolerance tests Y N Y N N NNNNNNNNNNNNNN
Exposure assessed at the individual level NNNNNNNNNYNNNNYYYNY
Exposure assessed using a biomarker of exposure NNNNNNNNNNNNNNNYYNN
Control for established diabetes risk factors in addition to age Y N Y N N N Y NNNNNNNNNNNY
Case–control and cross-sectional studies (n = 11)
Response rate among noncases at least 70%b Y —— Y N Y ——N—— N———N N —N
Noncases would have been cases if they had developed diabetes N — — N N N — — N N N Y — — — N N — N
Data collected in a similar manner for all participants Y — — Y N N — — N Y Y Y — — — N N — Y
Cases interviewed within 6 months of diagnosis N — — N N N — — N N N N — — — N N — N
Interviewer blinded with respect to the case status of the person interviewedc Y ——— N N——N N N Y ———N N — Y
Time period during which all participants were interviewed was the samec Y ——— N N——N Y Y N———N N — Y
Same exclusion criteria applied to all participants Y — — Y N N — — N Y N N — — — N N — Y
Cohort studies (n = 8)
Loss to follow-up was independent of exposure — N Y — — — N N — — — — N N N — — Y —
Intensity of search of disease independent of exposure status — N Y — — — N N — — — — N N N — — Y —
Abbreviations: —, not applicable; N, no; Y, yes. aCriteria modiﬁed from Longnecker et al. (1988). bNot applicable to two case–control studies based only on deaths (Rahman and Axelson
1995; Rahman et al. (1996). cNot applicable to the study using the National Health Insurance Database from Taiwan (Wang et al. 2003).
Table 5. Criteria for evaluating the design and data analysis of epidemiologic studies on arsenic and diabetes.a
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due to between-subject variability in water
consumption and to other sources of arsenic
exposure in these areas, such as contaminated
food and cooking water. On the other hand,
because arsenic exposure was assessed at the
village level and diabetes diagnosis was often
not performed according to standard proce-
dures, this ecologic association could reflect
the uncertain comparability of exposure
groups in terms of socioeconomic develop-
ment, access to care, study selection factors
and other diabetes risk factors. The use of
urine tests and of administrative data to iden-
tify diabetes makes it likely that only severe or
symptomatic cases were identified, and it is
uncertain whether the procedures and fre-
quency for diabetes testing were similar across
areas with different arsenic exposure. In addi-
tion, the use of administrative data can be
affected by surveillance and diagnostic biases.
For example in Taiwan, arsenic-related health
problems in the endemic areas are well
known, hence, subjects in these areas may
have received different medical care, including
different diagnostic services, compared with
subjects in areas with lower arsenic levels.
It is also possible that the findings from
Taiwan and Bangladesh may not be generaliz-
able to other populations. Some reasons for
this include variations in the distribution of
polymorphisms in genes involved in arsenic
metabolism or response (Loffredo et al.
2003), differences in arsenic species to which
populations were exposed (Chen et al. 1995),
other co-exposures (Chen et al. 1995), and
dietary deficiencies that may interact with
arsenic. For example, selenium and zinc levels
in Taiwan and Bangladesh are among the
lowest worldwide (Lin and Yang 1988), and
poor dietary selenium has been suggested as
an underlying factor for arsenic and cancer in
Bangladesh and West Bengal in India
(Spallholz et al. 2004). In guinea pigs, sele-
nium and arsenic counteract each other in
glucose metabolism (Das et al. 1989), and the
joint effect of high arsenic and low selenium
could play a role in diabetes development.
Exposure to arsenic, selenium, other nutri-
ents, and other diabetes risk factors were not
measured in epidemiologic studies.
We found no reports of diabetes in popu-
lations known to be exposed to high levels of
arsenic in drinking water in Chile and
Argentina. This lack of information on
diabetes could reﬂect a lack of research, but it
has also been suggested to be related to publi-
cation bias (Longnecker and Daniels 2001).
The evidence from general populations
outside of Taiwan or Bangladesh was inconclu-
sive because of the small number of cases, limi-
tations in study design, and misclassiﬁcation of
diabetes status. Occupational studies, on the
other hand, could not be interpreted in favor or
against an association because of uncertain
comparability of study participants with the
general population used as reference, limitations
in exposure assessment, lack of information on
concomitant exposures, lack of information on
major diabetes risk factors, and the possibility
of a healthy worker survivor effect.
An important conclusion we derived from
the epidemiologic review is the limited quality
of the evidence base. This ﬁnding is consistent
with previous reviews, including those by U.S.
and international panels (NRC 1999, 2001;
Ng 2001; WHO 2001). These panels deter-
mined that the available evidence on arsenic
and diabetes suffered from uncertainties in
study design and exposure assessment. Our
review further reﬁnes these reports and identi-
ﬁes the lack of biomarker data and the lack of
standard criteria for diabetes assessment as
major limitations of the evidence base.
Current uncertainties in the role of arsenic in
diabetes development could be reduced by
conducting carefully planned epidemiologic
studies in populations exposed to a wide range
of arsenic levels. Future studies should
a) measure appropriate arsenic biomarkers
that integrate all sources of exposure (e.g.,
urine or toenails); b) carefully collect informa-
tion on current and past sources of arsenic
exposure and on potential confounders and
modifiers, including known determinants of
diabetes development; c) and prospectively
ascertain diabetes using standard deﬁnitions.
Conclusion
The possibility of an association between
chronic arsenic exposure and diabetes has
implications for research and public health.
Millions of people are exposed worldwide to
moderate or high levels of arsenic in drinking
water. Because diabetes is also a major public
health problem, the public health consequences
of a causal association could be serious.
Methodologic problems limit the causal inter-
pretation of the moderately strong association
between high arsenic exposure and diabetes in
Taiwan and Bangladesh. Overall, the experi-
mental and epidemiologic evidence is at present
insufﬁcient and inadequate to establish causal-
ity. Experimental studies that use arsenic con-
centrations relevant to human exposures, and
high-quality prospective epidemiologic studies
that use appropriate methods for exposure
assessment as well as rigorous criteria for out-
come deﬁnitions should be research priorities.
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